NASDAQ · REGN
Regeneron Pharmaceuticals, Inc.
$818.77+$5.50 (+0.68%)
Regeneron Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.72% below the high.
Loading market information…
NASDAQ · INCY · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Incyte Corporation’s next earnings report is currently expected on Feb 9, 2027, with estimated earnings per share of $1.89. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Incyte Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 29, 2025 | $1.57+12.95% vs estimate | $1.22B-3.29% vs estimate |
|---|
| Q1 2025 | Apr 29, 2025 | $1.16+14.85% vs estimate | $1.05B-8.68% vs estimate |
|---|
| Q4 2024 | Feb 10, 2025 | $1.43-8.92% vs estimate | $1.18B+17.3% vs estimate |
|---|
THE ANALYST VIEW
44 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 15 contributors · Median target $139.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$818.77+$5.50 (+0.68%)
Regeneron Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.72% below the high.
$56.49-$0.80 (-1.4%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 5.8% below the high.
$66.20-$0.08 (-0.12%)
Exelixis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
$317.33-$1.45 (-0.45%)
Ligand Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
$15.45-$0.11 (-0.71%)
Cullinan Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.38% below the high.
